50 results about "Orthotopic tumor" patented technology

Methods and compositions are provided for the analysis of skin surfaces to determine the presence of neoplastic tissue. In the methods of the invention, a composition comprising a florescent probe that binds to a specific neoplasia associated marker is applied topically to the area of interest. After topical administration, the probe preferentially binds to markers associated in neoplastic lesions in situ, which binding is detected with a compact illumination unit that provides illumination at a wavelength appropriate for image acquisition. The illumination unit comprises a light source and fiber optic bundle to direct the light towards the area of examination. A detection unit is used to capture and record an image of the area of investigation. The detection unit may be a digital camera, film camera, etc. A mapping module may also be provided to catalogue the site of examination.

The invention discloses a reversible crosslinked biodegradable polymer vesicle having positive charges on an inner membrane, a preparation method thereof and application in preparation of antineoplastic drugs. The biodegradable polymer vesicle based on tumor targeting of a block polymer PEG-P (TMC-DTC)-SP or PEG-P (LA-DTC)-SP, having the positively charged membrane, reversibly crosslinked in reduction sensitivity and intracellularly solvable and crosslinked can effectively support and protect biological macromolecules such as proteins, DNA and siRNA and micromolecular drugs with negative charges in a physical environment and can be delivered to intravital tumor cells to induce apoptosis. The system has lots of unique advantages including simple and easy controllability of preparation, excellent biocompatibility, excellent controlled drug release property, super-strong in-vivo circulation stability, superior cancerous cell targeting and remarkable cancer cell apoptosis capability and the like. Therefore, the reversible crosslinked biodegradable polymer vesicle is expected to become a simple, stable, multifunctional nano system platform integrating multiple advantages and is used for efficient, active and targeted delivery from nucleic acids to in-situ tumors.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

The invention discloses a reversibly crosslinked biodegradable polymersome with an asymmetric membrane structure as well as a preparation method and application thereof to nucleic acid medicines. The polymersome and the preparation method have the advantages that a triblock polymer PEG-P(TMC-DTC)-PEI or PEG-P(DLLA-DTC)-PEI is synthesized and is self-assembled and self-crosslinked to obtain the polymersome with the asymmetric membrane structure or the triblock polymer is linked with a targeting molecule and is self-assembled to obtain targeting RCCPs; the inner shell of the polymersome is PEI and is used for compounding and loading nucleic acid through electrostatic interaction; a membrane is reversibly crosslinked biodegradable polyester / polycarbonate with good biocompatibility; dithiolane of a side chain is similar to a human body natural antioxidant lipoic acid; the outer shell of the polymersome takes PEG as the background and can target cancer cells; by studying that the carrier is compounded with functional siRNA and studying the gene silencing effects in vitro and vivo, in vivo blood circulation and bio-distribution, the condition of treating lung cancer in situ bearing mice and toxic and side effects of the polymersome, the polymersome is expected to become a nanosystem platform integrating the advantages of simplicity, stability, multifunction, and the like and is used for carrying out efficient and active targeting delivery on siRNA to tumors in situ.

The invention belongs to the field of microorganism animal cell system, and relates to an establishment method of a fluorescence visualization human hepatoma nude mice model which can self emit high strength red or green fluorescences and has the metastatic ability. After obtaining a human high-metastatic fluorescence hepatoma cell line HCCLM3-R, HCCLM3-G, HCCLM6-R and HCCLM6-G of fluorescence genes with high chromosome conformable degree, high fluorescence intensity and stable expression by using the method of pseudotype slow virus infection, hepatoma cells expressed by the fluorescences is placed beneath nude mice skin to establish a fluorescence visualization high-metastatic human hepatoma nude mice subcutaneous tumor model or subcutaneous fluorescence expression tumor tissues is placed in nude mice hepar to establish a fluorescence visualization high-metastatic human hepatoma nude mice hepar primary tumor model. The got model can be used as a tracer of animal in vivo hepatoma cells, and can be used for molecular mechanism study of hepatoma recurrence and metastatic and prophase therapeutic effect discrimination for new anti-hepatoma therapy and new anti-hepatoma drugs, etc.

The invention relates to the technical field of biomedicine, in particular to a mouse esophageal cancer model and a construction method thereof. The construction method includes: inducing mice by a chemical carcinogenic agent to construct a primary mouse esophageal cancer model to obtain an esophageal cancer in-situ tumor tissue; transplanting the esophageal cancer in-situ tumor tissue to naked mice subcutaneously, and performing in-vivo culture to obtain a transplanted tumor tissue; sequentially subjecting the transplanted tumor tissue to removal of part of fiber cells according to a rapid adherence method, enriching of epithelial tumor cells according to an epithelial culture method and removal of residual fiber cells according to a rapid digestion method, and separating to obtain the mouse esophageal cancer model. The mouse esophageal cancer model used for rapid construction of perfectly-immune mouse esophageal cancer model is constructed, and the stable and reliable mouse esophageal cancer model construction method is formed, so that a gap of the mouse esophageal cancer model is filled, current related problems caused by lack of the mouse esophageal cancer model is solved, anda suitable research tool is provided for tumor immunology research of esophageal cancers.

The invention discloses a preparation method of magnetic induction hyperthermia embolism microspheres. The preparation method comprises the following steps of by taking a dissolved matter obtained bydissolving biodegradable high molecular polymers with low transition temperature and super paramagnetic Fe3O4 nano-particles into dichloromethane as an oil phase, Span 80 as a surfactant and an aqueous solution dissolved with polyvinyl alcohol (PVA) as an internal water phase, dropwise adding a water phase in the oil phase under the conditions with low temperature and high shearing to form primaryemulsion; placing the primary emulsion in a membrane emulsification instrument for membrane emulsification under the low temperature condition; forming multiple emulsion in a continuous phase of an external water phase PVA after the primary emulsion permeates a membrane, and performing low-temperature solidification to obtain the magnetic induction hyperthermia embolism microspheres which meet the demand for clinic size. The obtained microspheres are arbitrarily adjustable in size in a range from 100 microns to 1000 microns, can realize rabbit orthotopic liver cancer model embolism hyperthermia under guidance of iconography and have potential application in the interventional hyperthermia field of orthotopic tumors.

The invention discloses microencapsulated human pancreatic carcinoma cells, and a preparation method and application thereof. The preparation method comprises the following steps of: adding suspension with human pancreatic carcinoma cells into Matrigel-containing sodium alginate solution; spraying into a calcium chloride solution in high voltage electrostatic environment to obtain microspheres; and performing ion exchange reaction on the microspheres and a sodium citrate solution, and thus obtaining the microencapsulated human pancreatic carcinoma cells. The obtained microencapsulated human pancreatic carcinoma cells have uniform size and the diameter of about 420mm. Cells in microcapsules are well proliferated, and grow in a three-dimensional way. The microencapsulated human pancreatic carcinoma cells are applied to subcutaneous tumor and in-situ tumor animal models, and have the advantages of high modeling success rate and quick tumor growth compared with the traditional tumor cell suspension injection method.

The invention discloses a pharmaceutical composition for chemotherapy and immunotherapy combined treatment. The pharmaceutical composition is prepared from: a first component alginate and a second component chemotherapeutic drug; the alginate can form a porous gel with calcium ions in a body, and the alginate is one or more of sodium alginate, potassium alginate and ammonium alginate; and the second component chemotherapeutic drug can cause immungentic cell death. The pharmaceutical composition belongs to an efficient tumor-specific immunotherapy program, the tumor in situ can be effectively killed, and the growth of distant metastatic tumors and the recurrence probability of tumor can be suppressed and reduced through immune response.

The invention belongs to the field of pharmaceutical preparations, and relates to an active targeting liposome carrier system for in situ tumors and lymphatic metastatic tumors. The carrier system is composed of polypeptides and liposomes whose amino acid sequence is CGNKRTRGC sequence of LyP-1. Wherein the LyP-1 sequence polypeptide is connected by two cysteines through a disulfide bond to form a ring structure. The liposome carrier system can passively drain the liposome into the lymphatic system through subcutaneous interstitial injection or intramuscular injection, and target the tumor metastasis lymph node through the mediated effect of LyP-1. The system can also be administered directly via intravenous injection, targeting tumors in situ and lymphatic metastases through tumor EPR effects and LyP-1-mediated effects. The liposome carrier system of the present invention can be used for targeted delivery of drugs for the diagnosis or treatment of tumors in situ and lymphatic metastases.

The invention belongs to the field of stem cells and biotechnology, and relates to a novel application of adipose-derived mesenchymal stem cells. Firstly, the invention provides a method for constructing adipose-derived mesenchymal stem cells carrying miR-122. In addition, the invention also discloses an application of the adipose-derived mesenchymal stem cells carrying miR-122 in the preparation of liver cancer chemosensitization preparations. The adipose-derived mesenchymal stem cells (AMSC) carrying miR-122 are used for preparing a chemosensitization agent and are combined with clinically conventional chemotherapeutic drugs so as to be applied to the chemotherapy of a liver cancer tumor-bearing mice model, so that the sensitivity of heterotopic or in-situ tumor tissues to the chemotherapeutic drugs can be obviously improved, the chemotherapy effect is enhanced, and the progress of the liver cancer is blocked. The dosage of the chemotherapeutic drugs can be reduced, and the chemotherapy side reaction is alleviated. The invention provides a technical support for preparing a novel liver cancer chemotherapy targeting sensitizer and a new method for the system chemotherapy of the liver cancer.

The invention discloses a preparation method and an application of a silicate long afterglow probe. Mesoporous silicon dioxide is used as a template, zinc nitrate, gallium nitrate, germanium nitrate,ytterbium nitrate, chromic nitrate and erbium nitrate are used as doped metal raw materials, the doped metal raw materials are dissolved in water and uniformly mixed, the mixture is dropwise added into the mesoporous silicon dioxide, roasting is performed at high temperature, and a pre-product is obtained after roasting is finished; then, functional modification is performed on the surface of thepre-product, and hydroxylation, amination and PEG modification are sequentially performed to obtain a modified pre-product; and finally, a photosensitizer silicon dichloride phthalocyanine is loaded to obtain the silicate long afterglow probe. The silicate long-afterglow probe has good biological safety, after caudal vein injection and under X-ray irradiation, a tumor area is effectively enriched,deep in-situ tumor imaging is achieved, in-situ tumor cells are seriously killed, and finally diagnosis and treatment integration of the silicate long-afterglow probe on deep tumors is achieved.

The invention discloses an application of bacteroides fragilis combined with an immune checkpoint inhibitor in treatment of skin tumors, in particular to a bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685, and the bacteroides fragilis ZY-312 is combined with a PD-1 inhibitor for use, so that the comprehensive curative effect of treating the skin tumors can be remarkably improved; the bacteroides fragilis can effectively prevent and treat generation, development, relapse and metastasis of melanoma by reducing the levels of proinflammatory factors IL-1, IL-6, IL-8 and VEGF, increasing migration of CD8 + effector T cells, reducing recruitment of Treg cells, reducing the weight of in-situ tumors and increasing the cancer inhibition rate, the harm of radiotherapy and chemotherapy to organisms is relieved, and the living quality of patients is improved.

The invention relates to the technical field of biological medicine, in particular to carrier-free self-assembled nanoparticles as well as a preparation method and an application thereof. The carrier-free self-assembled nano particle is composed of two drug molecules, namely, the photosensitizer and the imidazo quinoline Toll-like receptor stimulant, the preparation method is simple, and the problems that the two hydrophobic drug molecules are poor in water solubility and low in bioavailability are solved at the same time. Compared with other control groups, the photosensitizer chlorin and the Toll-like receptor stimulant nanoparticles (Ce6-IMDQ NPs) show a better in-situ tumor removal effect, and the growth of far-end tumors can be remarkably inhibited through photodynamic-immune combined treatment.

The invention provides a medicine used for tumor treatment. The medicine comprises an ORFV attenuated strain. A virulence gene deletion strain of the ORFV is prepared through deletion of virulence genes including ORFV001-ORFV008, ORFV020, ORFV024, ORFV073, ORFV112-ORFV131 and ORFV134, and the virulence gene deletion strain is the ORFV attenuated strain. The ORFV attenuated strain is used for anti-tumor drugs, prevents tumor cell growth, promotes tumor cell death, prevents in-situ tumor growth, prevents tumor metastasis, and increases the proportion of immune cells in the tumor.

The invention relates to the technical field of medicines, in particular to application of pimavanserin tartrate in preparation of a drug for treating glioma, the glioma is polymorphic glioblastoma, and the application for treating glioma at least has any one or more of the following uses: (a) inhibiting the proliferation of glioma cells; (b) inhibiting the migration of glioma cells; (c) arrestingthe tumor cell cycle at G1 / S phase; and (d) inhibiting the growth of intracranial tumor cells in situ. The pimavanserin tartrate is found to be an effective NFAT signal pathway inhibitor, can inhibitE2F and MYC signal pathways and ATR and AuroraA / B signal pathways in tumor cells at the same time, has high anti-GBM activity in vivo, can effectively penetrate through a blood brain barrier (BBB) toenter the brain, can effectively inhibit growth of intracranial tumors in situ through oral administration, and is convenient to use. The invention provides a novel therapeutic drug for treating GBMtumors, which has important clinical significance.

Provided are compositions and methods that involve cancer cells which are modified so that they can form orthotopic tumors in a non-human mammal, and wherein metastasis of the tumor can be controlled. The cancer cells, which may be human cancer cells, are modified so that expression of a human chemokine receptor can be modulated. Modulating expression of the human chemokine receptor allows selective initiation of metastasis. Kits which contain the modified cancer cells are provided. A method for identifying agents which can inhibit metastasis using non-human mammals having orthotopic tumors formed using the modified cancer cells is also included.

The invention discloses a method for preparing a tumor cell vaccine based on non-thermal plasma, and belongs to the field of biomedicine. According to the method, it is found that the non-thermal plasma can significantly kill tumor cells, such as melanoma cells; and injection of tumor cells inactivated by the non-thermal plasma can effectively inhibit tumor growth in vivo, or the non-thermal plasma can be used for direct irradiation on in-situ tumors so that the occurrence and development of metastatic tumors can be effectively inhibited, and new ideas are opened up for the subsequent application of the non-thermal plasma in the field of cancer treatment.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a metformin-based nano drug delivery system and a preparation method thereof. The metformin-based nano drug delivery system is characterized in that a metformin amphiphilic derivative and a histone deacetylase inhibitor pro-DHA are mixed and self-assembled in water, triptolide is entrapped at the same time to form cationic micelles OPTs, the cationic micelles OPTs are used for preparing the metformin-based nano drug delivery system, HA is adsorbed on the surface through electrostatic adsorption, and a multi-drug mixed micelle is constructed. According to the mixed micelle, OA-Met (or metformin), pro-DHA and Trip are simultaneously delivered to in-situ tumor tissues in a targeted manner through high affinity of HA and tumor cell surface overexpression CD44, the three medicines play a synergistic effect through different action mechanisms to prevent EMT and tumor metastasis, growth of in-situ tumors is effectively inhibited, the lifetime is prolonged, and the mixed micelle has a good application prospect. The metastatic tumor treatment effect is improved, and good in-vivo safety is achieved.

The invention belongs to the field of biological medicine, and discloses a magnetocaloric-immune combined medicine and an application thereof. The combined medicine comprises a magnetocaloric agent and an immunologic adjuvant, and the magnetocaloric agent is a ferromagnetic nanocrystal. The combined medicine is directly injected at a focus part, and an alternating magnetic field with specific field intensity is applied, so that tumor cells are killed, generated tumor cell fragments can be used as tumor antigens, and in combination with an immune amplification effect of an immunologic adjuvant, a tumor-like related vaccine effect can be generated, the in-situ tumors can be killed, and far-end tumor growth can be inhibited, and an efficient tumor treatment effect is provided; compared with photo-thermal therapy, the magnetic thermal therapy used in the invention has better tissue penetrability; and compared with traditional commercial Fe3O4 particles, the adopted magnetocaloric agent (ferromagnetic nanocrystals) has a better heat effect.

The present invention provides an application of miRNA-203a-3p to development of pancreatic cancer inhibiting drugs. 1) a model for screening the pancreatic cancer metastasis inhibiting drugs is prepared; 2) a model for inhibiting pancreatic cancer metastasis is prepared; and a nucleotide sequence of the miRNA-203a-3p is as shown in SEQ ID NO:1. It is discovered that the miRNA-203a-3p is incapableof inhibiting pancreatic cancer cell proliferation and tumorigenesis, but can induce negative correlation expression of a pancreatic cancer cell metastasis related gene CERKL, and can be used for preparing the mouse model for inhibiting the pancreatic cancer metastasis; and the model can be applied to screening of the pancreatic carcinoma metastasis inhibiting drugs and is used as a tool for researching a mechanism of development from in-situ tumor (pancreatic cancer) to metastatic tumor (pancreatic cancer).

The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent antitumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

The invention discloses an application of Bacteroides fragilis and / or zwitterionic capsular polysaccharide thereof in preparation of a medicine for treating respiratory system tumors, the Bacteroides fragilis, especially the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685 and the zwitterionic capsular polysaccharide thereof, can be used for preparing medicines for treating respiratory system tumors by increasing the levels of anti-tumor factors IL-12 and IFN-gamma, and can be used for preparing medicines for treating respiratory system tumors. The traditional Chinese medicine composition can be used for inhibiting expression of a tumor promoting factor IL-1beta, promoting up-regulation of the proportion of infiltrated CD8 + CD45 + T cells in tumors, regulating the microenvironment of tumor tissues, reducing the weight of in-situ tumors and inhibiting the number of tumor metastases, can be used for effectively preventing and treating respiratory system tumors, can be independently used for cancer treatment, and also can be used for preventing and treating tumors. The traditional Chinese medicine composition can also be combined with other treatment means such as microorganisms, operations, radiotherapy and chemotherapy, so that the comprehensive curative effect is remarkably improved, the harm of radiotherapy and chemotherapy to organisms is relieved, occurrence, development, relapse and metastasis of respiratory system tumors are effectively prevented, and the living quality of patients is improved.

A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma.

The invention provides a multi-functional antibody which is obtained through a genetic engineering technology, and synchronously has the biological effects of an IL-15 / IL-15R(alpha) compound as targeted PD1. The invention further discloses a nucleic acid molecule for encoding the antibody, a recombinant vector containing the nucleic acid molecule, a recombinant cell containing the recombinant vector, as well as a preparation method and medical application of the multi-functional antibody. The multi-functional antibody can effectively solve the problems of drug resistance and disease recurrenceof single-target antibody drugs, as well as more effectively kill tumor cells and prolong survival times of in-situ tumor model animals at a reduced effective dose. Compared with an IL-15 or IL-15 / IL-15 receptor compound, the multi-functional antibody is capable of prolonging serum half-life and improving tumor targeting property with toxic and side effects reduced.

The invention discloses a preparation method and an application of a silicate long afterglow probe. Mesoporous silicon dioxide is used as a template, zinc nitrate, gallium nitrate, germanium nitrate,ytterbium nitrate, chromic nitrate and erbium nitrate are used as doped metal raw materials, the doped metal raw materials are dissolved in water and uniformly mixed, the mixture is dropwise added into the mesoporous silicon dioxide, roasting is performed at high temperature, and a pre-product is obtained after roasting is finished; then, functional modification is performed on the surface of thepre-product, and hydroxylation, amination and PEG modification are sequentially performed to obtain a modified pre-product; and finally, a photosensitizer silicon dichloride phthalocyanine is loaded to obtain the silicate long afterglow probe. The silicate long-afterglow probe has good biological safety, after caudal vein injection and under X-ray irradiation, a tumor area is effectively enriched,deep in-situ tumor imaging is achieved, in-situ tumor cells are seriously killed, and finally diagnosis and treatment integration of the silicate long-afterglow probe on deep tumors is achieved.

The invention discloses a coronal gold-palladium nano heterogeneous material as well as a preparation method and application thereof, belongs to the technical field of photosensitive nano materials, and solves the technical problems that the photodynamic efficiency is low and metastatic cancer cells cannot be completely removed during photothermal / photodynamic synergistic treatment of cancers. Wherein the existence form of the gold element is a nanogold rod, the existence form of the palladium element is a bulge, the palladium bulge irregularly grows on the outer surface of the nanogold rod, and the mass ratio of the gold element to the palladium element is 1: (0.1-0.5). The prepared coronal gold-palladium nano heterogeneous material is used in drugs for killing in-situ tumor cells and inhibiting tumor recurrence and metastasis under a near-infrared light excitation condition. The coronal gold-palladium nano heterogeneous material prepared by the invention can effectively improve the photo-thermal and photodynamic efficiency of the material, kill in-situ tumor cells, induce generation of specific cytotoxic T lymphocytes, and effectively inhibit recurrence and metastasis of tumors.